May 5 (Reuters) - Valeant Pharmaceuticals International Inc (NYSE:VRX)
VRX.TO
* Board of directors will oversee patient access and pricing
committee
* Forms of a new patient access and pricing committee that
will be responsible for pricing of company's drugs
* Company will continue to work with hospitals to ensure
they have access to two drugs
* Committee will include a multi-disciplinary team of
valeant employees, including doctors, scientists, and other
executives
* Among other issues, committee will review pricing of
nitropress, isuprel, cuprimine, and syprine
* Valeant pharmaceuticals announces patient access and
pricing committee to oversee pricing of drugs
* Committee will be chaired initially by joseph papa ,
chairman and chief executive officer of valeant
* Company will continue to work with hospitals to ensure
they have access to nitropress and isuprel
Source text for Eikon: ID:nPn1srSFJa
Further company coverage: VRX.TO
(Bengaluru Newsroom: +1-646-223-8780)